APTX: Aptinyx Inc. - Summary | Jitta

Aptinyx Inc.

NASDAQ:APTX

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.10
Loss Chance
58.4%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (26)
Financial Strength (27)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
2.22
133.97%
3.06
156.54%
Biotechnology
6.24
36.38%
6.13
4.64%
6.36
42.83%
COMPANY DESCRIPTION
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.